Background: Human parvovirus B19(HPVB19) is a member of the large Parvoviridae family and, as a human pathogen, is responsible for various diseases. ¹⁾ In children, HPVB19 infections usually presents as red rash, which is often described as a“slapped cheek.” However, the presentation varies in adults. ²⁾ HPVB19 outbreaks mostly occur in the winter and spring. ¹⁾ The serum IgM test is the preferred means for diagnosing acute HPVB19 infections. ²⁾

Objectives: We investigated the epidemiology, clinical symptoms, and time course of HPVB19 infections in real-world practice by examining patients treated at a community hospital in Japan.

Methods: We studied adult patients with HPVB19 infections at Suwa Central Hosptial from April 2010 to November2019. Patients who were age 18 years or older, anti HPV B19 IgM antibody-positive, and symptomatic were included. We retrospectively examined the patients’ medical records to determine onset days, clinical symptoms and antinuclear antibody(ANA)-postitive rates. We defiend day 1 as the day when clinical symptoms first appeared.

Results: 53 patients were included in the study. Patient characteritistics were mean age 43 years, female 79.2%, mean period from onset to diagnosis 13days. Epidemic season were 4year cycle. ( Figure 1 ) Clinical symptoms and time course from onset day were upper respiratory symptoms(17.0%, 1.7days), fever(54.7%, 1.9days), abdominal symptoms(15.1%, 4.4days), edema(47.2%, 5.6days), arthralgia(71.7%, 6.6days), itching(15.1%, 6.9days), rash(62.3%, 8.9days) and lymphoadenopathy(30.2%, 10.2days). ( Figure 2 ) ANA positive rate was 50%(13/26) and average was 92.3.

Conclusion: 53 adult patients infected HPVB19 in 10 years at community hospital in Japan. Epidemic season were 4year cycle and skin eruption and joint symptoms appeared 4-5 days after upper respiratory symptoms. Previous study show that a second-phase illness with rash and arthralgia appear 10-11 days after the appearance of upper respiratory sympotms. ³⁾ In our study, a second-phase symptoms appeared about one week earlier than in previous study. Half of the patients were weakly ANA positive.

REFERENCES:

[1]Human Parvoviruses. Jianming Qie, Maria Soderlund-Venermo, Neal S. Young. Clinical Microbiology Reviews 2017; 30: 43-113

[2]Clinical Presentations of Parvovirus B19 Infection. Jessica T. LT COL, etc. American Family Physician 2007; 75: 373-6

[3]Experimental Parvoviral Infection in Humans. M J Anderson, etc. J Infect Dis 1985; 152: 257-65

Disclosure of Interests: None declared